X Section 1 obligation Instructio	16. Form 4 or										NGE C	-							
X Section 1 obligation Instructio	16. Form 4 or							Washington, D.C. 20549								OMB APPROVAL			
1. Name and	Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNERSHIP									OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
	on 1(b).			File	d pursuar or Sec	nt to Section 3	ection 16(a 0(h) of the	a) of the Se Investment	curitie t Con	es Exchan npany Act	ge Act of 1 of 1940	934							
1. Name and Address of Reporting Person <sup>*</sup> Lieu Hsiao D													i. Relationship of Reporting Person(s) to Issuer Check all applicable)						
													Director 10% Owner X Officer (give title Other (specify						
(Last) (First) (Middle) C/O NGM BIOPHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 04/05/2024								A below) below) Chief Medical Officer						
333 OYSTER POINT BOULEVARD													<ul> <li>b. Individual or Joint/Group Filing (Check Applicable ine)</li> <li>X Form filed by One Reporting Person</li> </ul>						
(Street)															•	rting Perso One Repoi			
SOUTH SAN FRANCISCO CA 94080					Dulo	Rule 10b5-1(c) Transaction Indication								Person					
(City)	(S	tate)	(Zip)									nt to a contr	act, instruction	or written pla	an that	is intended	to satisfy		
					the	affirma	ative defens	e conditions	of Ru	le 10b5-1(c	c). See Instru	iction 10.		or million pr					
1 Title of S	ecurity (Inct		ble I - Non	2. Trans			ities Ac	quired,	Dis	1	-		y Owned 5. Amour	nt of	6. 0.4	nership	7. Nature of		
Date				Day/Year)		ution Date	, Transa Code (I	Transaction Code (Instr.				Securities Beneficia Owned F	Securities F Beneficially (		: Direct Indirect str. 4)	Indirect Beneficial Ownership (Instr. 4)			
						Code	v	Amount	(A) o (D)	r Price	Transacti	Transaction(s) (Instr. 3 and 4)			(				
Common Stock 04/05					5/2024		U		19,349 D			0			D				
			Table II - I					uired, D s, option					Owned						
	2. Conversion	3. Transaction Date	3A. Deemed Execution Da	ansaction	5. N	umber of ivative		Exercisable and		7. Title and Amount of Securities		8. Price of Derivative	9. Numbe derivative		10. Ownership	p of Indirect			
Security (Instr. 3)	or Exercise Price of Derivative Security	(Month/Day/Year)	if any (Month/Day/Year)		de (Instr.			(Month/Day/Year)		r)	Underlying Derivative Secu (Instr. 3 and 4)		Security (Instr. 5)	Securities Beneficially Owned Following Reported	s Ily J	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)		
				-		3,4						Amount	-	Transaction (Instr. 4)		s)			
				Co	ode V	(A)	(D)	Date Exercisabl		xpiration ate	Title	or Number of Shares							
Restricted Stock Unit	(1)(2)	04/05/2024		Ι			39,750	(2)		(3)	Common Stock	39,750	(1)(2)	0		D			
Stock Option (Right to Buy)	<b>\$0</b> .84 <sup>(1)(4)</sup>	04/05/2024		Г			190,000	(4)	0	3/18/2029	Common Stock	190,000	(1)(4)	0		D			
Stock Option (Right to Buy)	\$0.84 <sup>(1)(4)</sup>	04/05/2024		I	>		25,000	(4)	0.	2/03/2030	Common Stock	25,000	(1)(4)	0		D			
Stock Option (Right to Buy)	\$0.84 <sup>(1)(4)</sup>	04/05/2024		I	>		100,000	(4)	0	3/16/2031	Common Stock	100,000	(1)(4)	0		D			
Stock Option (Right to Buy)	<b>\$0.84</b> <sup>(1)(4)</sup>	04/05/2024		I			150,000	(4)	0	3/02/2032	Common Stock	150,000	(1)(4)	0		D			
Stock Option (Right to Buy)	<b>\$0.84</b> <sup>(1)(4)</sup>	04/05/2024		Ι			150,000	(4)	1	1/03/2032	Common Stock	150,000	(1)(4)	0		D			
Stock Option (Right to Buy)	\$4.36 <sup>(1)(4)</sup>	04/05/2024		I			159,000	(4)	0	3/01/2033	Common Stock	159,000	(1)(4)	0		D			

1. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of \$1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").

2. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, as of the Effective Time, each outstanding Restricted Stock Unit was canceled and the holder of such canceled Restricted Stock Unit was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the Offer Price.

3. Restricted Stock Units do not have an expiration date.

4. Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

/s/ Valerie Pierce, Attorney-in-04/05/2024 Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.